Fibrinolysin

A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins.

Also Known As:

Networked: 1851 relevant articles (54 outcomes, 161 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Jensen, Boye L: 10 articles (08/2015 - 02/2009)
2.	Marder, Victor J: 10 articles (10/2013 - 07/2002)
3.	Svenningsen, Per: 9 articles (08/2015 - 02/2009)
4.	Trese, Michael T: 7 articles (01/2016 - 10/2007)
5.	Wu, Wei-Chi: 7 articles (01/2014 - 10/2007)
6.	Li, Jinan: 7 articles (08/2011 - 03/2005)
7.	Ny, Tor: 7 articles (08/2011 - 03/2005)
8.	Yang, Shun-Fa: 7 articles (01/2011 - 05/2003)
9.	Buhl, Kristian B: 6 articles (08/2015 - 09/2011)
10.	Friis, Ulla G: 6 articles (05/2015 - 02/2009)

Related Diseases

1.	Hemorrhage 04/01/2014 - "It seems that long-term prophylactic treatment with a dose of 10 IU/kg Fibrogammin could be effective in the prevention of CNS bleeding in the patients with F XIII deficiency. " 06/01/2014 - "In bleeders older than 30 days, plasmin-antiplasmin complex stayed elevated on day 5, but in patients with no bleeding complications, plasmin-antiplasmin level showed a declining trend. " 01/01/2013 - "Its ability to potently and specifically inhibit human plasmin (K(i) = 0.44 nM) makes it a potential therapeutic drug as a systemic anti-bleeding agent. " 06/01/2012 - "Major bleeding occurred in four patients (4.8%), and minor bleeding alone in 13 (15.7%), with no trend towards more bleeding at higher dosages of plasmin. " 01/01/2012 - "These include inhibition of the inflammatory effects of plasmin, effects on platelets and effects on factors V and VIII. If proven, these antithrombotic effects would have major implications for the systemic use of TXA in surgical patients, where TXA has been clearly shown to reduce bleeding. "
2.	Vitreous Detachment (Posterior Vitreous Detachment) 10/01/2004 - "To evaluate in a prospective study the efficacy of intrasurgical autologous plasmin enzyme (APE) in producing posterior vitreous detachment. " 01/01/2016 - "Plasmin can successfully cause vitreous liquefaction and induce a posterior vitreous detachment. " 01/01/2012 - "Plasmin plus SF(6) injection resulted in complete posterior vitreous detachment (PVD), whereas plasmin or SF(6) injection alone resulted in only partial PVD. " 03/01/2009 - "Intravitreal plasmin creates a posterior vitreous detachment, but may also liquefy the vitreous. " 06/01/2008 - "The use of plasmin for pharmacologic vitreolysis and the creation of a posterior vitreous detachment offers several potential advantages over surgery. "
3.	Neoplasms (Cancer) 07/01/2012 - "Most interestingly, cell-based assays showed that this flavonoid was effective in suppressing plasmin-induced loss of cancer cell adhesion. " 02/28/2015 - "Molecular modeling studies showed that NC1(XIX) and the anti-tumor fragment released by plasmin (F4) adopted locally the same type I β-turn conformation. " 12/01/2011 - "The present study revealed that plasmin was present in tumor tissue, and that it was responsible for processing progalanin to galanin(1-20) in the extracellular environment." 05/19/1997 - "In this study we have used mice lacking components of the PA/plasmin system to analyze the role of this system in the transformation process and in tumor growth. " 05/01/1996 - "It is concluded that these three cell lines constitute a valuable model system for in vitro studies of the role of cell surface uPA in cancer cell invasion and has application in the search for novel compounds which inhibit mechanisms involved in uPA-mediated plasmin generation on cancer cells."
4.	Thrombosis (Thrombus) 01/01/1985 - "To investigate the possibility that 99mTc-labelled acylplasmins are improved thrombus-detecting agents, six acylating agents were synthesised and their reaction with plasmin and the labelling of the products with 99mTc studies. " 01/01/1993 - "Results of recent studies suggest that recurrent thrombosis may be due to multiple factors including: plasmin-mediated activation of the coagulation system, procoagulant activity of the residual thrombus, presence of high shear forces that promote platelet deposition, and attenuation of physiologic fibrinolytic activity after pharmacologic thrombolysis. " 12/11/1958 - "[Studies on fibrinolysin activities in thrombosis]." 02/13/2015 - "The potent fibrinolytic enzyme, plasmin has numerous clinical applications for recannulizing vessels obstructed by thrombus. " 02/01/2015 - "Anti-ANXA2 Ab recognizes this complex, and these Ab can effectively promote thrombosis by inhibiting plasmin generation, and by activating endothelial cells. "
5.	Macular Edema 02/01/2004 - "To study the effect of autologous plasmin enzyme (APE) on the adhesion of the vitreous cortex to the internal limiting membrane (ILM) in eyes with diabetic macular edema. " 01/01/2012 - "Intravitreal autologous plasmin as a therapeutic modality for diffuse diabetic macular edema." 12/01/2010 - "The interval between onset of the macular edema and injection of autologous plasmin enzyme was 4.2 months. " 05/01/2005 - "Intrasurgical plasmin enzyme in diabetic macular edema." 10/01/2004 - "Intrasurgical plasmin enzyme in diabetic macular edema."

Related Drugs and Biologics

1.	Thrombin
2.	Fibrin
3.	Fibrinogen (Factor I)
4.	Serine Proteases (Serine Protease)
5.	Tissue Plasminogen Activator (Alteplase)
6.	fibrin fragment D (D-dimer)
7.	alpha-2-Antiplasmin (alpha 2 Antiplasmin)
8.	estropipate (Ogen)
9.	Aprotinin (Trasylol)
10.	Retinaldehyde (Retinal)

Related Therapies and Procedures

1.	Vitrectomy
2.	Intravitreal Injections
3.	Catheters
4.	Transplants (Transplant)
5.	Debridement